Literature DB >> 6347619

Drug interactions with warfarin.

M J Serlin, A M Breckenridge.   

Abstract

Drugs may interact with warfarin through pharmacodynamic or pharmacokinetic mechanisms. Examples of the former include alteration of the bioavailability of vitamin K by antibiotics, mineral oils or cholestyramine; oestrogens, diuretics and hypolipidaemic agents such as clofibrate may influence vitamin K-dependent clotting factor synthesis, and drugs which affect haemostasis, e.g. via platelet function, will enhance the anticoagulant effect of warfarin. Pharmacokinetic interactions are better understood. Few drugs have been shown to alter warfarin absorption, the importance of protein binding displacement has been exaggerated, and since warfarin is not eliminated to any extent unchanged by the kidney, the most important kinetic interactions are those due to inhibition or induction of its hepatic metabolism. Isomeric differences in metabolism form an important basis for stereoselective metabolic interactions, especially inhibition; this has been demonstrated with phenylbutazone, metronidazole and co-trimoxazole. Enzyme induction, although recognised for many years, may still pose problems in therapeutics, usually on withdrawal of the inducing agent.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347619     DOI: 10.2165/00003495-198325060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  75 in total

1.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

2.  Studies on the interaction of warfarin and clofibrate in man.

Authors:  R A O'Reilly; M A Sahud; A J Robinson
Journal:  Thromb Diath Haemorrh       Date:  1972-04-30

3.  Effect of diphenylhydantoin on the metabolism of dicoumarol in man.

Authors:  J M Hansen; K Siersbaek-Nielsen; M Kristensen; L Skovsted; L K Christensen
Journal:  Acta Med Scand       Date:  1971 Jan-Feb

4.  Interactions of benzodiazepines with warfarin.

Authors:  M Orme; A Breckenridge; R V Brooks
Journal:  Br Med J       Date:  1972-09-09

5.  Biphasic sulphinpyrazone-warfarin interaction.

Authors:  G G Nenci; G Agnelli; M Berrettini
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

6.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

7.  Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.

Authors:  D S Hewick; J McEwen
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

8.  Human sources and absorption of vitamin K in relation to anticoagulation stability.

Authors:  J A Udall
Journal:  JAMA       Date:  1965-10-11       Impact factor: 56.272

9.  Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.

Authors:  T D Bjornsson; P J Meffin; S Swezey; T F Blaschke
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

10.  Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids.

Authors:  E M Sellers; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

View more
  24 in total

1.  Lack of interaction between meloxicam and warfarin in healthy volunteers.

Authors:  D Türck; C A Su; G Heinzel; U Busch; E Bluhmki; J Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

2.  Effect of gefitinib on warfarin antithrombotic activity.

Authors:  Susumu Arai; Hisashi Mitsufuji; Yasuto Nishii; Sayaka Onoda; Shinichiro Ryuge; Mayuko Wada; Ken Katono; Maiko Iwasaki; Akira Takakura; Sakiko Otani; Michiko Yamamoto; Tomoko Yanaihara; Masanori Yokoba; Masaru Kubota; Masato Katagiri; Tomoya Fukui; Hirosuke Kobayashi; Nobuo Yanase; Ryuji Hataishi; Noriyuki Masuda
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

3.  Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Rajesh Krishna; Daria Stypinski; Melissa Ali; Amit Garg; Josee Cote; Andrea Maes; Bruce Degroot; Yang Liu; Susie Li; Sandra M Connolly; John A Wagner; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

4.  Clinically significant sucralfate-warfarin interaction is not likely.

Authors:  P J Neuvonen; A Jaakkola; J Tötterman; O Penttilä
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

Review 5.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 6.  Adverse drug interactions.

Authors:  M J Brodie; J Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-19

7.  Combining NSAIDs with anticoagulants: yes and no.

Authors:  J W O'Callaghan; R N Thompson; A S Russell
Journal:  Can Med Assoc J       Date:  1984-10-15       Impact factor: 8.262

8.  Prospective study of the potentiation of acenocoumarol by amiodarone.

Authors:  C Richard; B Riou; A Berdeaux; C Fournier; D Khayat; A Rimailho; J F Giudicelli; P Auzépy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 10.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.